Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

63.55
Delayed Data
As of May 25
 +5.74 / +9.93%
Today’s Change
49.96
Today|||52-Week Range
140.00
-32.49%
Year-to-Date
Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals Inc.
May 24 / MotleyFool.com - Paid Partner Content
Drawing Biopharma Concepts With A Crayon
May 23 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close57.81
Today’s open58.23
Day’s range58.23 - 64.64
Volume2,010,631
Average volume (3 months)1,025,403
Market cap$4.9B
Dividend yield--
Data as of 4:00pm ET, 05/25/2016

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-43.42%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book3.89

Competitors

 Today’s
change
Today’s
% change
IONSIonis Pharmaceutical...+1.89+5.66%
CRLCharles River Labora...-0.04-0.05%
ICLRICON PLC+1.19+1.77%
PRXLPAREXEL Internationa...+0.34+0.56%
Data as of 4:01pm ET, 05/25/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$1.21
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President &
Chief Operating Officer
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs